Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (FAERS) Database

Authors
1 Department of Pharmacy Practice, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, Bangalore, India
2 Department of Community Medicine, M.S. Ramaiah Medical College, Bangalore, India
Abstract
Background: Levonorgestrel is most commonly utilized as an emergency oral contraceptive. Little is known and/or studied about the adverse effects of levonorgestrel, therefore, current investigation was aimed to generate signal for unreported adverse drug reactions of levonorgestrel using disproportionality analysis in food and drug administration adverse events reporting system database. Methods: In FDA Adverse Events Reporting System (FAERS) database, all adverse event reports for levonorgestrel between January 2006 to June 2015 were identified and disproportionality analysis was conducted for selected adverse events of levonorgestrel using Reporting Odds Ratio, Proportional Reporting Ratio and Information Component with 95% confidence interval. Results: A disproportionality analysis was done for 15 adverse events of levonorgestrel; out of these, signal for 10 adverse events was found and among them menstruation delayed was reported maximum (1791), followed by pregnancy after post-coital contraception (942), breast tenderness (901), metrorrhagia (899), dysmenorrhea (822), menorrhagia (541), nipple disorder (141), breast enlargement (77), ectopic pregnancy (61) and premenstrual syndrome (35). Pregnancy after post-coital contraception showed the highest signal having the Information Component value of 129.2, Reporting Odds Ratio value of 6.51 and Proportional Reporting Ratio value of 6.49. Conclusion: In this paper, ten novel AEs were identified that were disproportionately reported with the use of LNG by using data mining techniques. Although a causal relationship cannot be established, the number of cases reported suggests that there might be an association. If confirmed by epidemiologic studies, the findings from this study would have potential implications for the use of LNG and patient management in clinical practice.
Keywords

  1. El Maghraby HA, Nafee T, Guiziry D, Elnashar A. Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 month follow up period. Middle East Fertil Soc J. 2015;20(3):131-7.
  2. Ozgoli G, Sheikhan Z, Dolatian M, Simbar M, Bakhtyari M, Nasiri M. Comparison of sexual dysfunction in women using depo-medroxyprogesterone acetate (DMPA) and cyclofem. J Reprod Infertil. 2015;16(2):102-8.
  3. Hedayati-Moghaddam MR, Eftekharzadeh-Mashhadi I, Fathimoghadam F, Pourafzali SJ. Sexual and reproductive behaviors among undergraduate university students in Mashhad, a city in northeast of Iran. J Reprod Infertil. 2015;16(1):43-9.
  4. Ibrahim ZM, Ahmed MR, Shaaban MM. Knowledge, attitude and practice of emergency contraception among health care providers in Ismailia, Egypt. Middle East Fertil Soc J. 2013;18(4):246-52.
  5. Cwiak C, Howard B, Hsieh J, Ricciotti N, Sucato GS. Sexual and contraceptive behaviors among adolescents requesting emergency contraception. J Pediatr Adolesc Gynecol. 2016;29(6):643-7.
  6. Provenzano-Castro B, Oizerovich S, Stray-Pedersen B. LNG-emergency contraceptive pills: what do Argentinean healthcare students know? Sex Reprod Healthc. 2017;12:93-9.
  7. Alshammari TM, AlMutairi EN. Use of an entacapone-containing drug combination and risk of death: analysis of the FDA AERS (FAERS) database. Saudi Pharm J. 2015;23(1):28-32.
  8. Strom BL. Pharmacoepidemiology. 4th ed. England: John Wiley & Sons; 2007. 889 p.
  9. Poluzzi E, Piccinni C, Raschi E, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). UK: Intech Open Access Publisher; 2012.
  10. Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017;8(5):145-56.
  11. Shohel M, Rahman MM, Zaman A, Uddin MM, Al-Amin MM, Reza HM. A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception. BMC Womens Health. 2014;14:54.
  12. Shamloo BK, Chhabra P, Freedman AN, Potosky A, Malin J, Weiss Smith S. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database. Drug Saf. 2012;35(6):507-18.
  13. Deshpande G, Gogolak V, Smith S. Data mining in drug safety. Pharm Med. 2010;24(1):37-43.
  14. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev. 1997;18(4):502-19.
  15. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519-23.
  16. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483-6.
  17. Barry M. Nipple Discharge. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. Boston: Butterworths; 1990.
  18. Gülay H, Bora S, Kìlìçturgay S, Hamaloğlu E, Göksel H. Management of nipple discharge. J Am Coll Surg. 1994;178(5):471-4.
  19. Sasaki KJ. Menstruation Disorders in Adolescents [Internet]. New York: Medscape; 2016 [cited: 2017 Dec 22]. Available from: http://emedicine.medscape.com/article/953945-overview#a6.
  20. Bégaud B. Dictionary of pharmacoepidemiology. 1st ed. UK: John Wiley & Sons, Ltd; 2002; p. 15-22.
  21. Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891-8.
  22. Calis KA, Rivlin ME. Dysmenorrhea Medication [Internet]. New York: Medscape; 2016 [cited: 2017 Dec 22]. Available from: https://emedicine.medscape.com/article/253812-medication.
  23. Ekström P, Akerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment--effect on uterine contractility. Br J Obstet Gynaecol. 1992;99(8):680-4.
  24. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug saf. 2001;24(3):233-7.
  25. Pereira PP, Cabar FR, Raiza LC, Roncaglia MT, Zugaib M. Emergency contraception and ectopic pregnancy: report of 2 cases. Clinics (Sao Paulo). 2005;60(6):497-500.